Granules India locks in sole FTF for generic LUMRYZ
The company's second sole first-to-file ANDA positions it for 180-day exclusivity in the U.S. narcolepsy market and strengthens its complex generics franchise.
— 1 earlier story on Granules India Ltd. →What's new
- Granules India secured sole first-to-file status for generic Sodium Oxybate ER (LUMRYZ).
- This is the company's second sole FTF; the first was for Amphetamine ER Tablets.
- The status could grant 180-day generic exclusivity in the U.S. narcolepsy market.
Why this matters
Granules is building a credible complex generics track record. A second sole FTF validates R&D capabilities and opens a meaningful revenue stream if final FDA approval comes through. However, four open FDA observations from a recent inspection add execution risk.
What we're watching
- Timeline for final FDA approval and launch.
- Size of the U.S. narcolepsy market for once-nightly oxybate.
- Resolution of the four Form 483 observations from the June 2026 inspection.
The full read
Granules India has bagged its second sole first-to-file ANDA, a generic version of LUMRYZ (sodium oxybate ER) for narcolepsy. The designation entitles the company to 180 days of generic exclusivity in the U.S. upon final FDA approval, a prize that typically locks out competition and boosts margins. The first such win came for Amphetamine ER; this one targets a larger specialty therapy area and signals growing R&D depth in complex generics. Yet the path from FTF status to revenue isn't automatic. Granules still faces four Form 483 observations from a June 2026 FDA inspection of its U.S. facility — open issues that must be resolved before any launch. Chairman Dr. Krishna Prasad Chigurupati called it an important step. For a company with latest quarterly sales of ₹1,471 crore and a market cap of ₹18,937 crore, a successful launch here could deliver a genuine earnings lever. The next test is the facility inspection outcome, not just the ANDA approval.
Questions answered
- What does 'sole first-to-file' status mean for Granules India?
- It means Granules was the first to file an ANDA for this generic and no other filer qualifies for the same exclusivity window. This makes them eligible for 180 days of generic marketing exclusivity upon final FDA approval, during which no other generic can enter the market.
- How big is the market for LUMRYZ?
- The filing does not disclose market size, but the analyst rationale describes LUMRYZ as having 'substantial commercial potential'. The product is a once-nightly treatment for narcolepsy with cataplexy or excessive daytime sleepiness.
- What are the risks to this opportunity?
- The main risks are final FDA approval, which is not guaranteed, and timely launch. Additionally, Granules has four open FDA observations from a June 2026 inspection at its U.S. unit, which could affect manufacturing compliance. The company says it's voluntarily addressing them.
- How does this fit into Granules' broader strategy?
- Granules is shifting from basic active pharmaceutical ingredients and oral solids toward complex generics. This second sole FTF reinforces its R&D credibility and could diversify revenue beyond its base business. The company's trailing revenue growth is 22.8%, and this could add a high-margin product line.
- When might Granules launch the generic?
- The timeline depends on FDA review and final approval. The ANDA has been accepted as sole FTF, but the filing does not specify a target approval date. Typically, first-to-file exclusivity starts upon launch after approval, but patent litigation or settlement could also affect timing.
- What is the financial impact likely to be?
- Granules does not quantify it. A 180-day exclusivity window for a niche product could generate meaningful revenue, but the amount depends on market size, pricing, and market share. For context, the company's latest quarterly sales were ₹1,471 crore, so any additional revenue would be additive.
Granules India Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GRANULES →- 6 Jul 2026 · 8:37 AM IST Granules India locks in sole FTF for generic LUMRYZ
- 33d ago Granules India's US unit gets FDA inspection report with four open observations